Intrust Bank NA purchased a new position in BioTelemetry, Inc. (NASDAQ:BEAT) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 7,472 shares of the medical research company’s stock, valued at approximately $250,000.

Several other hedge funds have also recently made changes to their positions in BEAT. Teachers Advisors LLC increased its stake in BioTelemetry by 2.6% in the fourth quarter. Teachers Advisors LLC now owns 43,489 shares of the medical research company’s stock valued at $972,000 after buying an additional 1,099 shares during the period. Louisiana State Employees Retirement System increased its stake in BioTelemetry by 2.7% in the first quarter. Louisiana State Employees Retirement System now owns 11,600 shares of the medical research company’s stock valued at $336,000 after buying an additional 300 shares during the period. Russell Investments Group Ltd. increased its stake in BioTelemetry by 16.9% in the first quarter. Russell Investments Group Ltd. now owns 450,895 shares of the medical research company’s stock valued at $13,054,000 after buying an additional 65,030 shares during the period. Emerald Advisers Inc. PA increased its stake in BioTelemetry by 5.4% in the first quarter. Emerald Advisers Inc. PA now owns 24,271 shares of the medical research company’s stock valued at $703,000 after buying an additional 1,237 shares during the period. Finally, Bowling Portfolio Management LLC increased its stake in BioTelemetry by 22.4% in the first quarter. Bowling Portfolio Management LLC now owns 28,112 shares of the medical research company’s stock valued at $814,000 after buying an additional 5,146 shares during the period. Institutional investors and hedge funds own 77.99% of the company’s stock.

BioTelemetry, Inc. (NASDAQ BEAT) opened at 37.05 on Thursday. BioTelemetry, Inc. has a 12 month low of $15.25 and a 12 month high of $37.50. The stock has a market cap of $1.20 billion, a PE ratio of 24.87 and a beta of 0.76. The firm has a 50-day moving average of $34.67 and a 200 day moving average of $30.14.

BioTelemetry (NASDAQ:BEAT) last posted its earnings results on Tuesday, August 8th. The medical research company reported $0.23 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.02. The firm had revenue of $58.10 million during the quarter, compared to analysts’ expectations of $58.39 million. BioTelemetry had a net margin of 21.03% and a return on equity of 18.75%. The company’s revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.20 earnings per share. Analysts anticipate that BioTelemetry, Inc. will post $0.99 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/31/intrust-bank-na-purchases-shares-of-7472-biotelemetry-inc-beat.html.

Several research firms recently weighed in on BEAT. BidaskClub upgraded shares of BioTelemetry from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 16th. Sidoti reiterated a “buy” rating and issued a $49.00 target price (up previously from $42.00) on shares of BioTelemetry in a report on Thursday, August 10th. Dougherty & Co lifted their target price on shares of BioTelemetry from $37.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, August 9th. Zacks Investment Research upgraded shares of BioTelemetry from a “hold” rating to a “strong-buy” rating and set a $39.00 target price for the company in a report on Friday, August 11th. Finally, Lake Street Capital reiterated a “buy” rating and issued a $50.00 target price (up previously from $35.00) on shares of BioTelemetry in a report on Friday, July 14th. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $44.40.

BioTelemetry Company Profile

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Want to see what other hedge funds are holding BEAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTelemetry, Inc. (NASDAQ:BEAT).

Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Stock Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related stocks with our FREE daily email newsletter.